Drugs / NPI-002
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05026632 | Jan 2022 → Sep 2026 overdue | cataract | Nacuity Pharmaceuticals, Inc. | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2023-07-11 | Nacuity Pharmaceuticals, Inc. | Results Nacuity Pharmaceuticals Advances Phase 1/2 Clinical Trial Evaluating NPI-002 Intravitreal Implant for the Delay of Cataract Progression nacuity.com ↗
Promising safety signals have been observed in the initial subjects. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2024-04-30 | Nacuity Pharmaceuticals, Inc. | Nacuity Pharmaceuticals Announces First Patients Implanted in Final Cohort of Phase 1/2 Clinical Trial Evaluating NPI-002 Intravitreal Implant for the Delay of Cataract Progression nacuity.com ↗ |
| 2023-07-11 | Nacuity Pharmaceuticals, Inc. | Nacuity Pharmaceuticals Advances Phase 1/2 Clinical Trial Evaluating NPI-002 Intravitreal Implant for the Delay of Cataract Progression nacuity.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NPI-002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05026632 ↗ |
| Route | Intravitreal | “NPI-002 Intravitreal Implant” NCT05026632 ↗ |